Home > Insider Trading > Filing (0001209191-23-018460)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1223348	Jr F Charles Wagner	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210	Evp & Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-03-10	361	$286.64	57,772	No	4	S	Direct
Common Stock	Disposition	2023-03-10	515	$287.83	57,257	No	4	S	Direct
Common Stock	Disposition	2023-03-10	327	$288.91	56,930	No	4	S	Direct
Common Stock	Disposition	2023-03-10	30	$289.44	56,900	No	4	S	Direct
Common Stock	Disposition	2023-03-10	541	$291.47	56,359	No	4	S	Direct
Common Stock	Disposition	2023-03-10	185	$292.68	56,174	No	4	S	Direct
Common Stock	Disposition	2023-03-10	27	$293.61	56,147	No	4	S	Direct
Common Stock	Disposition	2023-03-10	102	$294.94	56,045	No	4	S	Direct
Common Stock	Disposition	2023-03-13	24	$288.31	56,021	No	4	S	Direct
Common Stock	Disposition	2023-03-13	420	$292.41	55,061	No	4	S	Direct
Common Stock	Disposition	2023-03-13	1,153	$293.35	54,448	No	4	S	Direct
Common Stock	Disposition	2023-03-13	715	$294.52	53,733	No	4	S	Direct
Common Stock	Disposition	2023-03-13	292	$295.89	53,441	No	4	S	Direct
Common Stock	Disposition	2023-03-13	62	$296.77	53,379	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1.
Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $286.64 (range $286.17 to $287.16).
Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.30 to $288.20).
Open market sales reported on this line occurred at a weighted average price of $288.91 (range $288.37 to $289.34).
Open market sales reported on this line occurred at a weighted average price of $291.47 (range $291.10 to $292.00).
Open market sales reported on this line occurred at a weighted average price of $292.68 (range $292.14 to $293.12).
Open market sales reported on this line occurred at a weighted average price of $294.94 (range $294.85 to $295.35).
Open market sales reported on this line occurred at a weighted average price of $292.41 (range $291.97 to $292.82).
Open market sales reported on this line occurred at a weighted average price of $293.35 (range $292.99 to $293.80).
Open market sales reported on this line occurred at a weighted average price of $294.52 (range $294.13 to $294.81).
Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.33 to $296.32).